Icosavax initiates Phase 2 trial of IVX-A12 against RSV, hMPV

Icosavax announced the initiation of a Phase 2 clinical trial of IVX-A12, a combination bivalent respiratory syncytial virus, RSV, and human metapneumovirus, hMPV, virus like particle, VLP, vaccine candidate, in older adults. IVX-A12 is a liquid, refrigerator-stable formulation comprised of IVX-121, Icosavax’s RSV prefusion F protein VLP vaccine candidate, and IVX-241, Icosavax’s hMPV prefusion F protein VLP vaccine candidate. The company previously announced positive topline interim Phase 1 results for IVX-A12 in May 2023. “The initiation of this Phase 2 trial for IVX-A12 marks another important milestone for Icosavax, as we advance this potential first-in-class combination vaccine candidate into mid-stage development,” said Adam Simpson, Chief Executive Officer of Icosavax. “We are highly encouraged by the recent findings from the Phase 1 study of IVX-A12 and believe that it has the potential to address an unmet need as the first bivalent vaccine candidate against both RSV and hMPV, two of the leading causes of pneumonia in adults.”